系统性红斑狼疮患者淋巴细胞粘附分子表达的观察

用流式细胞术及免疫双荧光染色法，分析了３５例系统性红斑狼疮（ＳＬＥ）患者外周血淋巴细胞粘附分子表型（ＣＤ＿（１１ａ）／ＬＦＡ－ｌα、ＣＤ＿（１８）／ＬＦＡ－１β、ＣＤ＿（５４）／ＩＣＡＭ－１）。结合淋巴细胞变化对ＳＬＥ作进一步探讨。结果发现ＳＬＥ活动期ＣＤ＿（１１ａ）、ＣＤ＿（１８）表达随ＣＤ＿４细胞减少而降低、ＣＤ＿８细胞增多而增高，ＣＤ＿（５４）在ＣＤ＿（２０）细胞上亦增高。此外，ＣＤ＿８细胞的ＣＤ＿（１８）增高与ＣＤ＿４ＣＤ＿（４５）ＲＡ￣＋细胞降低呈负相关（Ｐ＜０．０５），而与ＣＤ＿（２０）细胞的ＣＤ＿（５４）增高呈正相关（Ｐ＜０．０１）。提示粘附分子可能在ＳＬＥ发病机理中具有重要意义。     

GM—CSF及IL—4增强肝癌患者树突状细胞免疫功能

目的　探讨粒／ 巨噬细胞集落刺激因子（ ＧＭＣＳＦ） 及白介素４（ＩＬ４） 对正常成人及肝癌患者树突状细胞（ＤＣ） 表面人白细胞抗原（ＨＬＡ）ＤＲ 及Ｂ７２ 等免疫分子表达及其免疫功能的影响。方法　以ＧＭＣＳＦ 及ＩＬ４ 联合刺激正常成人（ｎ ＝ １０） 及肝癌患者（ｎ ＝ １０）ＤＣ,检测经ＧＭＣＳＦ 及ＩＬ４ 联合刺激前后ＤＣ 表面ＨＬＡＤＲ 及Ｂ７２ 表达水平及ＤＣ 免疫功能变化。结果　经ＧＭＣＳＦ 及ＩＬ４ 联合刺激后ＤＣ 表面ＨＬＡＤＲ 及Ｂ７２ 表达水平在肿瘤患者（６－７ ±１－６ 、６－１ ±１－１ 增至１３－１ ±２－３ 、１１－４ ±２－０ＶＯＦ,Ｐ＜ ０－０１） 及正常成人（１０－７ ±１－４ 、９－６ ±１－２ 增至１４ ±２－２ 、１１ ±１－７ＶＯＦ,Ｐ＜ ０－０５） 均有增高;该ＤＣ 免疫诱导能力亦相应增强（ 肝癌患者：由３１００ ±１２０ 增至６４００ ±１４０ｃｐｍ ,Ｐ＜ ０－０１ ;正常人：由６２００ ±９０ 增至７０００ ±１１０ｃｐｍ ,Ｐ＞ ０－０５） 。结论　ＧＭＣＳＦ 及ＩＬ４ 联合刺激能增强正常成人及肝癌患者ＤＣ 表面ＨＬＡＤＲ 及Ｂ７２ 表达水平并进一步增强ＤＣ 免疫功能。提示联合应     

急性心肌梗塞病人血清sIL—2R水平,mIL—2R和T淋巴细胞亚群的变化

目的探讨急性心肌梗塞发病中免疫指标的变化。方法应用单克隆与多克隆双抗体夹心法检测６６例急性心肌梗塞（ＡＭＩ）病人发病后第１周内血清可溶性白细胞介素－２受体（ｓＩＬ－２Ｒ）的变化，同时检测外周血淋巴细胞膜白细胞介素－２受体（ｍＩＬ－２Ｒ）表达及Ｔ淋巴细胞亚群的变化。结果ＡＭＩ病人血清ｓＩＬ－２Ｒ明显增高，ｍＩＬ－２Ｒ表达明显降低，与对照组比较差异有极显著性意义（Ｐ＜０．００１）。发病后第１ｄ至第７ｄ，ｓＩＬ－２Ｒ增高和ｍＩＬ－２Ｒ表达降低一直比较明显。ＡＭＩ病人ＣＤ４、ＣＤ８和ＣＤ４／ＣＤ８明显低于对照组（Ｐ＜０．００１），以第１ｄ降低最明显，以后逐渐升高，ＣＤ８于第７ｄ恢复正常。４ｄ内死亡者和伴有室性心律失常（ＶＡ）者上述指标变化更明显。结论血清ｓＩＬ－２Ｒ水平、ｍＩＬ－２Ｒ表达和Ｔ淋巴细胞亚群变化与ＡＭＩ病情和预后有密切关系。     

高血压病人白细胞流变性与细胞粘附分子表达的变化

目的探讨白细胞流变性和细胞粘附分子（ＣＡＭＳ）表达与高血压发生及病情严重程度的关系。方法采用红细胞变形能力测定仪、体外血栓血小板粘附两用仪和酶联免疫吸附法（ＥＬＩＳＡ），检测１４９例高血压病人和１１０例健康人外周血白细胞变形能力（ＬＤ）、白细胞粘附功能（ＬＡＦ）、白细胞ＣＤ１８表达及血清可溶性细胞间粘附分子－１（ｓＩＣＡＭ－１）浓度的变化。结果高血压病人白细胞滤过指数（ＬＦＩ）、白细胞粘附率（ＬＡＲ）、白细胞ＣＤ１８表达和ｓＩＣＡＭ－１浓度均明显增高，与对照组比较差异有极显著性（Ｐ＜０．００１），三期病人各指标之间比较差异也具有极显著性（Ｐ＜０．００１），且以第３期病人各指标增高最明显。高血压病人ＬＡＲ与ＬＦＩ呈正相关（ｒ＝０．５７９，Ｐ＜０．００１）；ＬＡＲ和ＬＦＩ与白细胞ＣＤ１８表达和ｓＩＣＡＭ－１浓度呈正相关（ｒ＝０．６６２～０．８０４，Ｐ＜０．００１）。结论ＬＤ降低、ＬＡＦ及白细胞ＣＤ１８表达和ｓＩＣＡＭ－１浓度增高参与高血压的发生，且与病情严重程度有密切关系。     

冬虫夏草多糖脂质体对肝炎后肝硬化患者T细胞免疫调节作用的研究

应用脂质体包埋冬虫夏草多糖口服３个月治疗肝炎后肝硬化２８例，在治疗前、后第２、３个月分别检测外周血Ｔ细胞免疫功能指标和肝功能。结果：①ＰＨＣ患者外周血ＣＤ４细胞比例，ＣＤ４／ＣＤ８比值、自然杀伤细胞活性及经ＰＨＡ－Ｐ诱导的外周血淋巴细胞、膜白细胞介素２受体（ＭＩＬ－２Ｒ）的表达，白细胞介素２（ＩＬ－２）和＋γ－干扰素（ＴＦＮ－γ）的生成均显著低于正常对照（Ｐ值分别＜０．００１，＜０．０１，＜０．０     

HIV/HBV合并感染患者的 CD4+T淋巴细胞计数与HBV DNA的关系

目的 了解人免疫缺陷病毒（ＨＩＶ） ／乙型肝炎病毒（ＨＢＶ） 合并感染者的 ＣＤ４ ＋ Ｔ 淋巴细胞与其基线肝功能和乙肝病毒（ ＨＢＶ ＤＮＡ） 水平的关系。 方法 对尚未开始高效抗逆转录病毒治疗（ ＨＡＡＲＴ） 的ＨＩＶ ／ＨＢＶ 合并感染患者 ６９ 例进行基线 ＣＤ４ ＋ Ｔ 淋巴细胞、ＨＢＶ ＤＮＡ 检测。 结果 ＣＤ４ ＋ Ｔ 淋巴细胞≤１００个 ／μｌ 组患者的 ＨＢＶ ＤＮＡ 显著高于 ＣＤ４ ＋ Ｔ 淋巴细胞 ＞ １００ 个 ／μｌ 组（Ｐ ＜ ０． ０５）。 ＣＤ４ ＋ Ｔ 淋巴细胞计数与ＨＢＶ ＤＮＡ 成负相关（ｒ ＝ － ０ ３４４,Ｐ ＜ ０． ０５）。 结论 随着患者 ＡＩＤＳ 病情进展,ＨＩＶ ／ＨＢＶ 合并感染者的 ＨＢＶ ＤＮＡ 复制水平增高。     

急性冠状动脉综合征合并糖耐量减低对纤溶系统的影响

目 的：分析急性冠状动脉综合征（ＡＣＳ）患者合并糖耐量异常对Ｄ－二聚 体（ＤＤ）含量 的 影 响。方 法：选 择１３５例住 院 治 疗 的ＡＣＳ患者。根据糖代谢情况,患者被分为单纯ＡＣＳ组（４８例）,２型糖 尿 病（Ｔ２ＤＭ）＋ＡＣＳ组（４６例）和糖 耐 量 减 低（ＩＧＴ）＋ＡＣＳ组（４１例）;同期住院健康体检者３５例作为正常对照组。测定 比 较 各 组 的浆ＤＤ水平。结 果：与正常对照组和单纯ＡＣＳ组比 较,Ｔ２ＤＭ＋ＡＣＳ组和ＩＧＴ＋ＡＣＳ组的甘油三酯水平［（１．１２±０．３９）ｍｍｏｌ／Ｌ,（１．５２±０．９２）ｍｍｏｌ／Ｌ比（２．５７±１．１７）ｍｍｏｌ／Ｌ,（２．３２±０．９６）ｍｍｏｌ／Ｌ］显著 升 高（Ｐ均＜０．０１）;与正常对照组比较,单纯ＡＣＳ组、Ｔ２ＤＭ＋ＡＣＳ组和ＩＧＴ＋ＡＣＳ组患 者 血 浆ＤＤ水平［（３６０．５０±７４）ｎｇ／ｍｌ比（７９５．２４±１３４．１０）ｎｇ／ｍｌ比（６６３．３１±１１６．０６）ｎｇ／ｍｌ,（７０２．４０±１２６．６４）ｎｇ／ｍｌ］均显 著 升 高（Ｐ均＜０．０１）;而Ｔ２ＤＭ＋ＡＣＳ组和ＩＧＴ＋ＡＣＳ组的 血 浆ＤＤ水平显著低于单纯ＡＣＳ组（Ｐ均＜０．０５）。结论：急 性 冠 状动脉综合征合并糖耐量减低患者纤溶系统功能较单纯ＡＣＳ患者 减 退。     

霉酚酸酯治疗难治性狼疮性肾炎肾组织病理的变化

目的：进一步阐明霉酚酸酯（ＭＭＦ）对难治性Ⅳ型狼疮性肾炎（ＬＮ）患者肾组织学改变的影响,探讨ＭＭＦ作用机制。方法：对１５例接受ＭＭＦ治疗（０．７５～１．５ｇ／ｄ）的难治性Ⅳ－ＬＮ患者进行重复肾活检,穿刺组彩色分析系统。肾组织ＣＤ４＾＋ＣＤ８＾＋细胞当色、细胞附分子（ＩＣＡＭ－１）和血管细胞粘附分子１（ＶＣＡＭ－１）表达采用ＰＡＰ四导有后上述各项指标的改变。结果：（１）ＭＭＦ治疗后肾组织活动性指数明     

肝癌组织及血清中细胞间粘附分子-1表达的研究

目的研究细胞间粘附分子－１（ｉｎｔｅｒｃｅｌｕｌａｒａｄｈｅｓｉｏｎｍｏｌｅｃｕｌｅ－１，ＩＣＡＭ－１）作为判断肝癌发展程度及转移状态指标的可能性。方法以免疫组化的方法检测ＩＣＡＭ－１在肝癌组织和正常肝组织中的表达，观察了ＩＣＡＭ－１表达在细胞的定位。以点免疫印迹法测定不同患者血清和不同肝组织中ＩＣＡＭ－１的表达。分析ＩＣＡＭ－１表达与肿瘤生长转移状态、肿瘤特性的关系。结果肝癌细胞ＩＣＡＭ－１表达阳性（阳性率为８００％），主要分布在细胞膜，正常肝细胞则为阴性。肝癌患者血清可溶性细胞间粘附分子－１（ｓＩＣＡＭ－１）水平高于正常人（Ｐ＜００１）及肝良性肿瘤患者（Ｐ＜００５），肝癌伴转移者高于无转移者（Ｐ＜００５）。肝癌组织中ＩＣＡＭ－１含量明显高于癌旁组织（Ｐ＜００１）及正常肝组织（Ｐ＜００１），而与肿瘤大小及有无包膜无关（Ｐ＞００５）；转移组肝癌中ＩＣＡＭ－１的表达明显高于非转移组（Ｐ＜００５），两组癌旁组织中ＩＣＡＭ－１表达无差别（Ｐ＞００５）。结论血清及组织中ＩＣＡＭ－１的水平在一定程度上可以反映肝癌发展程度及转移状态，有可能作为预测肝癌转移复发的指标。     

二甲基硫脲对心肌细胞抗过氧化氢损伤的实验研究

为探讨二甲基硫脲（ＤＭＴＵ）保护心肌细胞抗过氧化氢（Ｈ２Ｏ２）损伤。３２瓶培养乳鼠心肌细胞随机分４组，每组８瓶：（１）对照组；（２）Ｈ２Ｏ２（５ｍｍｏｌ）组；（３）ＤＭＴＵ（２０ｍｍｏｌ）组；（４）Ｈ２Ｏ２（５ｍｍｏｌ）＋ＤＭＴＵ（２０ｍｍｏｌ）组。在３７℃、５％ＣＯ２的ＭＥＭ培养４小时。结果发现：（１）与对照组比，Ｈ２Ｏ２组乳酸脱氢酶（ＬＤＨ，Ｕ／１００ｍｌ）释放多（２８２．３８±４７．２８比７７．２５±１８．２５，Ｐ＜０．０１）、ＴＢＡ反应物（ＴＢＡＲＳ，ｎｍｏｌ／ｍｇＰｒ．）产生多（２．２５±０．５３比０．７９±０．３６，Ｐ＜０．０１）；（２）与Ｈ２Ｏ２组比，Ｈ２Ｏ２＋ＤＭ－ＴＵ组ＬＤＨ释放少（９９．２５±４１．８８比２８２．３８±４７．２８，Ｐ＜０．０１）；ＴＢＡＲＳ产生少（０．５９±０．１８比２．２５±０．５３，Ｐ＜０．０１）；此外，我们还发现ＤＭＴＵ组超氧化物歧化酶（ＳＯＤ，μｇ／ｍｇＰｒ．）比对照组高（８．４９±３．６５比１．９２±１．４０，Ｐ＜０．０１）。ＤＭＴＵ能保护心肌细胞抗Ｈ２Ｏ２损伤，机制与灭活羟自由基（·ＯＨ）、保护ＳＯＤ活性有关     

Affordable CD4(+) T-cell counts on 'single-platform' flow cytometers I. Primary CD4 gating

Here, we demonstrate the flow cytometric concept of 'primary CD4 gating' utilizing three different CD4 monoclonal antibodies (mAbs) conjugated with five different fluorochromes. CD4(+) lymphocytes were defined by an autogate in a single histogram of CD4 fluorescence intensity (FI) (y-axis) vs. side light scatter (x-axis). A wide range of absolute counts for > 600 individuals, including HIV(+) patients, were compared with those obtained by 'state-of-the-art' single-platform flow cytometers such as the volumetric Ortho CytoronAbsolute and the Becton Dickinson FACSCalibur using TruCount beads. The correlation between CD4 counts obtained with primary CD4 gating and the full test panel on the Ortho Cytoron was excellent (R(2) = 0.999). Bland-Altman statistics showed a mean difference of -2 cells/mm(3) [confidence interval (CI) 95% = -3 to -1; limits of agreement -27 to +23]. In addition to absolute CD4 counts, CD4% values and CD4/CD8 ratios are also frequently requested. To obtain these, lymphocytes need to be counted using scatter gates, and a second tube stained with a CD8 mAb to count CD8(++) lymphocytes can be incorporated. We conclude that primary CD4 gating on single-platform volumetric flow cytometers is one of the most economical and flexible technologies for routine cost-conscious service work, particularly during the follow-up of patients undergoing anti-HIV therapy and/or vaccination in the developing world.     

Cell surface expression of CD25, CD54, and CD95 on B- and T-cells in chronic lymphocytic leukaemia in relation to trisomy 12, atypical morphology and clinical course

BACKGROUND: Surface antigen expression can be used to define subgroups of patients with different clinical courses in chronic lymphocytic leukaemia of the B-cell type (CLL). PURPOSE-METHODS: To study the clinical significance of functional markers linked to proliferation (CD25), adhesion (CD54), and apoptosis (CD95) on B- and T-cells in 68 patients with CLL using dual colour flow cytometry (FCM). RESULTS: The mean proportion of CD19+ B-cells expressing CD25 was significantly higher in CLL patients compared to controls (P=0.02), while CD54+ and CD95+ B-cells did not differ significantly. In CLL with atypical morphology and in patients with trisomy 12, the mean percentage of CD25+ B-cells was lower than in typical CLL (P<0.02) and in patients with disomic tumor cells (P<0.03). Patients with 30% of CD25+ B-cells had a shorter median time to treatment than CD25-negative cases (P=0.01). A low CD54 expression was associated with a prolonged median time to treatment (P=0.004), low WBC counts (P<0.05), and low S-LDH (P=0.03). A high CD95 expression was correlated with elevated S-LDH (P=0.02) and a finding of lymphadenopathy (P=0.02). In individual patients there was a strong correlation between B- and T-cell expression of CD25 (P<0.0001), CD54 (P=0.0002), and CD95 (P=0.0002), respectively. CONCLUSIONS: CD25 and CD54 expression on CD19+ cells seems to give prognostic information. The strong correlation between the expression of CD25, CD54 and CD95 on B-and T-cells suggests that the expression of these antigens is not an inherent characteristic of the malignant B-cell clone.     

Aberrant co-expression of CD19 and CD56 as surrogate markers of acute myeloid leukemias with t(8;21) in Taiwan

Aberrant antigen expression in acute myeloid leukemia (AML) has been extensively studied in the West with limited reports from Taiwan. We carried out this retrospective study to characterize the frequency and significance of aberrant antigen expression of AML in Taiwan. Among 111 cases, 58 (52%) showed aberrant antigen expression, most frequently CD7 (27%) and CD56 (23%). Aberrant CD7 expression was observed in all non-AML-M3 subtypes, most frequently in AML-M7 (4/6, 67%); while CD19 expression was only observed in AML-M2 (5/36, 14%). CD56 expression was most common in AML-M5 (4/8, 50%). The relative frequency of CD19 and CD56 expression in AML with t(8;21) was higher than those with other chromosomal abnormalities or normal karyotype (P = 0.011 and 0.005, respectively). In non-M3 AML, aberrant antigen expression was identified in 56/96 (58%) cases, in contrast to 2/15 (13%) AML-M3 cases (P = 0.001). CD7, CD19 and CD56 expression was not correlated with remission rate. We concluded that aberrant immunophenotype was more frequent in non-M3 leukemias in Taiwan. The relative frequency of CD19 and/or CD56 expression in AML with t(8;21) was significantly higher than those without this translocation and co-expression of these two antigens may serve as the surrogate markers for AML with t(8;21).     

慢性丙型肝炎患者外周血单个核细胞HCV RNA检测及其与机体免疫功能的相关性研究

目的观察慢性丙型肝炎患者外周血单个核细胞(PBMC)HCVRNA含量及其对T淋巴细胞亚群的影响,以探讨HCV感染者PBMC中HCVRNA水平及其与机体免疫功能的关系。方法采用荧光定量PCR(FQPCR)技术对128例丙型肝炎患者血清、外周血单个核细胞的HCVRNA含量进行了检测,同时检测CD3+、CD4+、CD8+、CD4+/CD8+。结果PBMC内HCVRNA阳性组与HCVRNA阴性组比较,前者CD3+、CD4+水平降低、CD8+水平增高,CD4+/CD8+比值下降大于后者,差异有显著性(P<0.05)。结论丙型肝炎病毒侵染PBMC后可加重患者的细胞免疫功能紊乱。     

Overexpression of complement receptors and related antigens on the surface of bone marrow mast cells in patients with systemic mastocytosis

Depending on their stage of maturation and other factors, mast cell (MC) subsets differ from each other in terms of the expression of complement-associated antigens. This study analysed the expression of various complement-related cell surface antigens (CD11b/CR3, CD11c/CR4, CD35/CR1, CD55/DAF, CD59/MIRL, CD88/C5aR) on bone marrow mast cells (BMMC) in patients suffering from systemic mastocytosis (SM), other haematological diseases and non-haematological disorders (control groups). Expression of complement-associated cell surface antigens was analysed by flow cytometry. There were clear immunophenotypic differences between BMMC obtained from patients with SM and those from the control subjects: the percentage of patients expressing surface CD11c, CD35 and CD88 was significantly higher in patients with SM (76%, 100%, 54%) than in the control subjects (58%, 11%, 18%) (P < 0.05). In addition, the levels of CD11c, CD35 and CD88 expressed per MC (sites per cell) were significantly higher (P < 0.05) in SM than in the control group. Expression of the complement regulatory molecules CD55 and CD59 was detected in BMMC in all patients analysed. However, the levels of CD59 per BMMC were higher in patients with SM as compared with the control subjects, which could help to explain the formation of BMMC aggregates in the former group of individuals. Together, our results showed that BMMC in systemic mastocytosis overexpressed the cell surface membrane receptors involved in binding of complement components and complement-mediated cell activation. Whether this pathological expression of complement receptors is of pathophysiological significance remains to be determined.     

移植心脏特异性免疫耐受的实验研究——供体脾细胞诱导大鼠移植心脏特异性免疫低反应的研究

本实验采用大鼠异位心脏移植模型,观察到:术前多次输注供体大鼠脾细胞可显著延长移植心存活时间,其作用呈供体抗原特异性,作用机理与受体大鼠T亚群改变及血清免疫抑制因子的产生有关。结果提示术前单用供体抗原难以达到移植心免疫耐受。     

Expression of intercellular adhesion molecule 1 (ICAM-1) in childhood acute lymphoblastic leukaemia: correlation with clinical features and outcome

To investigate whether expression of intercellular adhesion molecule 1 (ICAM-1, CD54) in childhood acute lymphoblastic leukaemia (ALL) has an impact on the biological behaviour of the disease, we evaluated 751 children of the ALL-BFM 90 trial with B-cell precursor- ( n  = 6777) or T-cell-ALL ( n  = 74) for CD54 expression within immunological subgroups, its correlation to certain clinical features, and therapy outcome.
The highest percentage of patients expressing CD54 was found in common- and pre-B-ALL (76.1% and 61.4%, respectively). There was intermediate expression in pre-pre-B-ALL (47.8%), and the lowest expression was detected in T-ALL (12.2%).
A significant positive correlation could be demonstrated between low CD54 expression (< 20% stained blasts) and high peripheral leucocyte counts, central nervous system (CNS) involvement, and splenomegaly at the time of diagnosis ( P  < 0.01). In addition, CD54 expression was a favourable but not independent prognostic factor. Event-free survival estimate at 4.5 years was 86% for CD54⁺ patients ( n  = 463), compared with 78% for CD54⁻ patients ( n  = 241) ( P  < 0.01). These findings demonstrate that CD54 expression has an impact on dissemination patterns and outcome of childhood ALL, and emphasizes the potential relevance of adhesion mechanisms in influencing clinical characteristics and prognosis of haematological malignancies.     

Expression of co-stimulatory and adhesion molecules and chemokine or apoptosis receptors on acute myeloid leukaemia: high CD40 and CD11a expression correlates with poor prognosis

The expression of adhesion and co-stimulatory molecules, and chemokine and death receptors such as tumour necrosis factor (TNF) and FAS on acute myeloid leukaemia (AML) may influence the biology of the disease and response to chemotherapy and immunotherapy. In this study, we analysed the expression of these molecules in 99 AML patients using monoclonal antibodies and flow cytometry, and correlated the expression with French-American-British (FAB) classification and survival. The following molecules were studied: the co-stimulatory molecules CD80, CD86 and CD40; the adhesion molecules CD11a-c, CD31, CD43, CD50, CD54, CD102, CD58 and CD62L; the chemokine receptor CXCR4; and the death receptors TNFR1 and TNFR2 and FAS. The expression of all molecules was significantly higher in the M4/M5 FAB subgroups except for CD80, CD43, CD54 and CD62L. The AML M3 subgroup had a significant lower expression of CD11a (P = 0.02) and CD11c (P = 0.03). Five-year survival was significantly shorter in cases of high CD40 expression [> 20% positive cells, relative risk (RR) 2.56, P = 0.02] or high CD11a expression (> 80% positive cells, RR 2.6, P = 0.03). This effect was most prominently present in the AML M4/M5 FAB subgroups. We conclude that the expression levels of adhesion and co-stimulatory molecules, CXCR4 and apoptosis-receptors are predominantly FAB subtype-related with high CD40 and CD11a expression as poor prognostic factors.     

Effect of anti-CD11b (αM-MAC-1) and anti-CD54 (ICAM-1) monoclonal antibodies on indomethacin induced chronic ileitis in rats

Leukocyte emigration from blood to sites of inflammation involves sequential interaction of specific adhesion molecules expressed by both leukocytes and endothelial cells. The central steps in leukocyte-endothelial adhesive interactions are leukocyte rolling, sticking, and transmigration. This study investigated the effect of monoclonal antibodies against CD54 (ICAM-1) and CD11b (α^M-chain of MAC-1) on intestinal inflammation. Anti-CD54 and anti-CD11b were tested in rats with indomethacin-induced chronic ileitis. Macroscopic changes were assessed by a modified version of the Wallace et al. score. Leukocyte rolling and sticking were investigated by intravital microscopy. Results show that indomethacin administration led to a chronic inflammatory response characterized by significant increase (P<0.05) in rolling (from 5.41±2.87 to 32.41±15.03 100 μm^–1 s^–1) and sticking (from 0.16±0.18 to 9.11±5.3 100 μm^–1 s^–1) leukocytes. After antibody treatment only the anti-CD11b group showed significant (P<0.05) reduction in rolling (from 32.41±15.03 to 6.6±2.7 100 μm^–1 s^–1) and sticking (from 9.11±5.3 to 0.07±0.09 100 μm^–1 s^–1) leukocytes. This was also the case for macroscopic changes. Indomethacin led to a rise in the Wallace score from 0 to 4.29±0.76 points (P<0.05) and anti-CD11b to a reduction from 4.29±0.76 to 1.29±1.11 points (P<0.05). Anti-CD54 and combined anti-CD11b/CD54 administration was not followed by significant changes. Therefore we suggest that leukocyte-based CD11b but not endothelial-based CD54 contributes most to leukocyte adhesion in the setting of indomethacin-induced ileitis in rats. Accepted: 7 September 1999     

胃癌及淋巴结转移灶中CD44v6和上皮钙粘素的表达及其意义

目的 :探讨 CD4 4 v6和上皮钙粘素 (E- cd)在胃腺癌及淋巴结转移灶中的表达及其意义。方法 :应用免疫组化 SABC法检测 2 0例正常胃粘膜 ,2 0例异形增生 ,185例胃癌原发灶及 10 9例淋巴结转移灶中 CD4 4 v6和 E- cd表达。结果 :CD4 4 v6和 E- cd在异型增生、胃癌原发灶及淋巴结转移灶中阳性表达率分别为 2 0 .0 0 % (4/ 2 0 )、66.4 9% (12 3 / 185 )和87.18% (10 2 / 10 8)以及 85 .0 0 % (17/ 2 0 )、5 2 .97% (98/ 185 )和 2 6.5 0 % (3 1/ 117)。三者之间有显著差异 (P<0 .0 1)。CD4 4 v6表达率与胃癌生长方式、组织学类型、血管淋巴管内浸润及 TNM分期无关。 E- cd阳性表达与胃癌生长方式、组织学类型及 TNM分期显著相关。早期肠型胃癌 CD4 4 v6阳性表达率显著高于弥漫型 (P<0 .0 5 ) ,在进展期胃癌则无显著差异。E- cd的阳性表达率下降主要见于弥漫型胃癌。结论 :CD4 4 v6和 E- cd阳性表达同胃癌分化及生物学行为密切相关 ,是预测其侵袭转移有价值的指标。同时 ,此结果也支持胃癌两种不同起源的假说。